One-year claims analysis comparing inhaled fluticasone propionate with zafirlukast for the treatment of asthma.

BACKGROUND Randomized clinical trials have demonstrated that fluticasone propionate (FP) has better objective as well as subjective clinical outcomes than zafirlukast (ZA) in the treatment of asthma. OBJECTIVE The goal of this study was to determine whether the superiority of FP over ZA observed in clinical trials is supported under actual practice conditions. METHODS A retrospective cohort analysis of pharmacy and medical claims for asthma was performed. Patients were identified who had at least 1 ICD-9 (493.XX) claim for asthma and were recently prescribed inhaled FP or ZA. Subjects could not have had a claim for any inhaled corticosteroid or oral leukotriene modifier in the 9 months before initiation of FP or ZA. They were subsequently observed for 12 months. RESULTS A total of 725 persons were new users of FP and 309 of ZA. FP was associated with a 70% reduced risk for hospitalization (P =.0232), a 49% lower risk for an emergency department event (P =.0546), and a 51% reduction in combined emergency department events and hospitalizations (P =.0268) when compared with ZA. Adjusted annual asthma care costs declined significantly for FP and increased for ZA. The adjusted mean difference in annual asthma costs was $215 less per patient for FP (P <.0001). CONCLUSION Asthma care costs decreased for patients treated with FP and increased for patients treated with ZA. Furthermore, FP-treated patients had significantly lower risks of asthma-related hospitalization than ZA patients. This study supports results seen in clinical trials comparing these two medications.

[1]  J. Concato,et al.  Randomized, controlled trials, observational studies, and the hierarchy of research designs. , 2000, The New England journal of medicine.

[2]  S J Pocock,et al.  Randomized trials or observational tribulations? , 2000, The New England journal of medicine.

[3]  L. Edwards,et al.  Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma. , 2000, The Journal of allergy and clinical immunology.

[4]  R. Stanford,et al.  The cost of asthma in the emergency department and hospital. , 1999, American journal of respiratory and critical care medicine.

[5]  Lynn Wei,et al.  Oral Montelukast, Inhaled Beclomethasone, and Placebo for Chronic Asthma , 1999, Annals of Internal Medicine.

[6]  J. Kotsanos,et al.  Panel 3: methodological issues in conducting pharmacoeconomic evaluations--retrospective and claims database studies. , 1999, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[7]  J. Boivin,et al.  First treatment with inhaled corticosteroids and the prevention of admissions to hospital for asthma , 1998, Thorax.

[8]  W. Busse Inflammation in asthma: the cornerstone of the disease and target of therapy. , 1998, The Journal of allergy and clinical immunology.

[9]  N. Katakami,et al.  Increased use of inhaled corticosteroids and reduced hospitalizations in adult asthmatics: 11 years' experience in a Japanese hospital , 1998, Respirology.

[10]  R. Balkrishnan,et al.  PGD9 Outcomes and Cost‐Benefit of Inhaled Corticosteroid Therapy Introduction in Medicaid‐Enrolled Asthmatic Children , 1998 .

[11]  J. Donahue,et al.  Inhaled Steroids and the Risk of Hospitalization for Asthma , 1998 .

[12]  M. Blaiss,et al.  Outcomes analysis in asthma. , 1997, JAMA.

[13]  J Grana,et al.  The Use of Administrative Data to Risk-Stratify Asthmatic Patients , 1997, American journal of medical quality : the official journal of the American College of Medical Quality.

[14]  G. Higgins New US asthma guidelines stress early, aggressive treatment , 1997 .

[15]  D. Keeley,et al.  New guidelines on asthma management , 1997, BMJ.

[16]  P. Gergen,et al.  An economic evaluation of asthma in the United States. , 1992, The New England journal of medicine.

[17]  M. Goldman,et al.  Decrease in asthma mortality rate in Israel from 1991-1995: is it related to increased use of inhaled corticosteroids? , 2000, The Journal of allergy and clinical immunology.

[18]  D. Malone,et al.  A national estimate of the economic costs of asthma. , 1997, American journal of respiratory and critical care medicine.

[19]  D. Stempel,et al.  Use of a pharmacy and medical claims database to document cost centers for 1993 annual asthma expenditures. , 1996, Archives of family medicine.

[20]  R B Haynes,et al.  Guidelines for the clinical and economic evaluation of health care technologies. , 1986, Social science & medicine.